The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 11, 2014

Filed:

Aug. 15, 2012
Applicants:

Jeremy E. Wulff, Victoria, CA;

Michael G. Brant, Victoria, CA;

Jeremy W. Mason, Sarnia, CA;

Caleb M. Bromba, Fort St. John, CA;

Martin J. Boulanger, Victoria, CA;

Inventors:

Jeremy E. Wulff, Victoria, CA;

Michael G. Brant, Victoria, CA;

Jeremy W. Mason, Sarnia, CA;

Caleb M. Bromba, Fort St. John, CA;

Martin J. Boulanger, Victoria, CA;

Assignee:

UVic Industry Partnerships Inc., Victoria, British Columbia, CA;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/381 (2006.01); C07D 333/78 (2006.01); C07C 279/16 (2006.01); C07C 279/22 (2006.01); C07C 67/08 (2006.01); C07C 215/44 (2006.01); C07C 35/31 (2006.01); C07C 211/41 (2006.01); C07C 67/29 (2006.01); C07C 29/56 (2006.01); C07C 233/52 (2006.01);
U.S. Cl.
CPC ...
C07C 279/16 (2013.01); C07C 279/22 (2013.01); C07C 67/08 (2013.01); C07C 215/44 (2013.01); C07C 35/31 (2013.01); C07C 2102/22 (2013.01); C07C 211/41 (2013.01); C07C 67/29 (2013.01); C07C 29/56 (2013.01); C07D 333/78 (2013.01); C07C 233/52 (2013.01);
Abstract

Disclosed embodiments concern the synthesis and use of therapeutic compounds that for treating emerging flu strains and minimizing resistance to such strains. Methods for making the disclosed compounds concern using a base-mediated addition/cyclization sequence followed by functional group manipulation to develop functionalized compounds that can target neuraminidase, which makes them ideal candidates for treating influenza. Pharmaceutical compositions comprising the therapeutic compounds and biologically-acceptable materials are also described. Methods of inhibiting neuraminidase in subjects that are suspected of containing neuraminidase are also described. The use of metabolites of the disclosed compounds can also be used in diagnostic assays for therapeutic dosing of the disclosed compounds.


Find Patent Forward Citations

Loading…